Rezatapopt Shows Early Promise in TP53 Y220C-Mutant Tumors in PYNNACLE Phase II Trial on December 01, 2025 Familial mitral valve prolapse ORR ovarian neoplasm p53 reactivator Phase 2 Clinical Trials PYNNACLE trial Rezatapopt Solid Neoplasm Targeted Therapy TP53 gene Y220C mutation +
PMV Pharma's p53 Drug Shows Effect in Ovarian Cancer, but Financial Challenges Loom on September 11, 2025 cash runway Clinical Trials Familial mitral valve prolapse File (record) Frequency of Responses Funding ovarian neoplasm TP53 gene United States Food and Drug Administration +